Published in

American Association for the Advancement of Science, Science, 6573(374), p. 1343-1353, 2021

DOI: 10.1126/science.abl8912

Links

Tools

Export citation

Search in Google Scholar

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates

Journal article published in 2021 by Kizzmekia S. Corbett ORCID, Matthew Gagne ORCID, Danielle A. Wagner ORCID, Sarah O’ Connell, Sandeep R. Narpala ORCID, Dillon R. Flebbe, Shayne F. Andrew ORCID, Rachel L. Davis, Barbara Flynn, Timothy S. Johnston ORCID, Christopher D. Stringham ORCID, Lilin Lai, Daniel Valentin, Alex Van Ry ORCID, Zackery Flinchbaugh and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

A look at variant-specific boosters The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) has raised the question of whether current COVID-19 vaccines protect against VOCs and if a variant specific vaccine may be needed. Of the currently identified VOCs, the Delta variant is believed to be the most transmissible, whereas the Beta variant appears to be the most vaccine resistant. Corbett et al . looked at the effect of vaccine boosting using either the original WA-1 strain vaccine or a Beta variant–specific booster. Around 6 months after the primary two-dose vaccine series, a third boost vaccination resulted in higher neutralizing antibody levels against VOCs in nonhuman primates. Regardless of whether the boost was from the original vaccine or the Beta-specific version, similar increases in neutralizing antibody levels were observed and resulted in enhanced viral protection. —PNK